© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
April 14, 2021
The National Institute of Health has supported early testing of the artificial retina. Now, scientists are testing whether manufacturing it on the International Space Station results in a viable treatment for people with blinding eye diseases.
April 13, 2021
Bausch + Lomb and Novaliq GmbH have announced statistically significant topline data from the first phase 3 trial analyzing the investigational drug NOV03 as a first-in-class eye drop to treat dry eye disease associated with MGD.
April 12, 2021
‘Revolutionary Eye and Vision Research’ theme of annual meeting.
April 12, 2021
In an update, the CDC noted that the chances of an individual contracting COVID-19 from surface transmission is low.
April 12, 2021
Santen, Massachusetts Eye and Ear, Ulster University researchers will focus on ways to preserve vision by slowing, reversing, or preventing the damage.
April 09, 2021
Ocuphire Pharma’s ZETA-1 trial will investigate the potential of APX3330 to offer an oral treatment for diabetic retinopathy.
April 08, 2021
A diminishment of both hearing and vision is linked to an increased risk for dementia and mental decline, according to a new study.
April 07, 2021
Minimizing clinic visits, maximizing use of imaging modalities are key.
April 07, 2021
Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device has received FDA approval for use in ophthalmic surgery.
April 06, 2021
According to Verizon Business, BlueJeans Telehealth is way for providers and patients to conduct data-driven virtual care conversations.
